Supriya Lifescience Limited has announced that its Ambernath facility has received the World Health Organisation (WHO) Good Manufacturing Practices (GMP) certification for inhalation dosages. The audit was conducted by WHO on September 2, 2025, and upon completion, the facility was declared GMP-compliant.
In the exchange filings, the company shared, “This is to inform you that the World Health Organisation (WHO) on September 2, 2025 had conducted WHO GMP for Inhalation Dosages The Audit was conducted and upon completion WHO has issued WHO-GMP certificate for our Ambernath facility and declared that the Company is GMP complaint and can now carry out production and sale at our said facility and is eligible for further distribution of products in Rest of the World markets/ eligible markets.”
With this certification, the company can now carry out production and sale at the Ambernath facility and is eligible for further distribution of its products in eligible international markets.
The certification was received on September 30, 2025, and the company confirmed that no violations or contraventions were reported. Supriya Lifescience also stated that this development is not expected to have any material impact on current business operations or existing supplies from the facility.